Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - bluebird bio, Inc. | d742372dex991.htm |
| EX-99.2 - EX-99.2 - bluebird bio, Inc. | d742372dex992.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 14, 2014
bluebird bio, Inc.
(Exact name of registrant as specified in its charter)
| DELAWARE | 001-35966 | 13-3680878 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 150 Second Street Cambridge, MA |
02141 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (339) 499-9300
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure
On June 16, 2014, bluebird bio, Inc. (“bluebird”) conducted an investor webcast summarizing clinical data from its HGB-205 clinical trial that was presented at an oral presentation at the 19th European Hematology Association Congress in Milan, Italy on June 14, 2014. A copy of the presentation is being furnished as Exhibit 99.2 to this Report on Form 8-K.
The information in Item 7.01 of this Report on Form 8-K and Exhibit 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing
Item 8.01 Other Events
On June 14, 2014, issued a press release announcing clinical data from its HGB-205 clinical trial at an oral presentation at the 19th European Hematology Association Congress in Milan, Italy on June 14, 2014. The full text of bluebird’s press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit |
Description | |
| 99.1 | Press release issued by bluebird bio, Inc. on June 14, 2014. | |
| 99.2 | Investor presentation provided by bluebird bio, Inc. on June 16, 2014. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 16, 2014 | bluebird bio, Inc. | |||
| By: | /s/ Jason F. Cole | |||
| Jason Cole | ||||
| Senior Vice President, General Counsel | ||||
EXHIBIT INDEX
| Exhibit |
Description | |
| 99.1 | Press release issued by bluebird bio, Inc. on June 14, 2014. | |
| 99.2 | Investor presentation provided by bluebird bio, Inc. on June 16, 2014. | |